Postlicensure Observational Safety Study of 13vPnC Administered to Infants and Toddlers

NCT01128426

Last updated date
Study Location
Northern California Kaiser Permanente
Oakland, California, 94612, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Pneumococcal Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
2-3 months
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Infants starting vaccination with 13vPnC in the first 6 months of life who are members of the Northern California Kaiser Permanente healthcase system and who receive at least 1 dose of 13vPnC during the study observation period will be included. Infants must not have had 7vPnC at the time of 13vPnC dose administration.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Infants and children who were previously vaccinated with any number of doses of 7vPnC
will be excluded.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Pneumococcal Disease20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants
NCT04546425
  1. Brussels,
  2. Praha 6,
  3. Tallinn,
  4. Tallinn,
  5. Tallinn,
  6. Tartu,
  7. Helsinki,
  8. Bydgoszcz,
  9. Krakow,
  10. Krakow,
  11. Leczna,
  12. Lodz,
  13. Siemianowice Slaskie,
  14. Torun,
  15. Trzebnica,
  16. Warszawa,
  17. Wroclaw,
  18. Bratislava,
  19. Horne Srnie,
  20. Liptovská Osada,
  21. Edegem,
  22. Jindrichuv Hradec,
  23. Jindrichuv Hradec,
  24. Jindrichuv Hradec,
  25. Pardubice,
  26. Praha 3,
  27. Sezemice,
  28. Espoo,
  29. Helsinki,
  30. Järvenpää,
  31. Kokkola,
  32. Oulu,
  33. Pori,
  34. Seinajoki,
  35. Tampere,
  36. Turku,
ALL GENDERS
42 Days+
years
MULTIPLE SITES
Pneumococcal Disease20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants
NCT04530838
  1. Toyota-shi, Aichi
  2. Chiba-shi, Chiba
  3. Funabashi-city, Chiba
  4. Yotsukaido-shi, Chiba
  5. Fukui-shi, Fukui
  6. Fukuoka-City, Fukuoka
  7. Fukuoka-city, Fukuoka
  8. Iizuka, Fukuoka
  9. Gifu-city, Gifu
  10. Ebetsu Shi, Hokkaido
  11. Sapporo shi, Hokkaido
  12. Sapporo, Hokkaido
  13. Akashi-City, Hyōgo
  14. Kawasaki-shi, Kanagawa
  15. Kumamoto Shi, Kumamoto
  16. Kumamoto-shi, Kumamoto
  17. Nagano-shi, Nagano
  18. Ureshino-shi, Saga
  19. Hanyu-shi, Saitama
  20. Kumagaya-shi, Saitama
  21. Fuchu-city, Tokyo
  22. Setagaya-ku, Tokyo
  23. Setagaya-ku, Tokyo
  24. Setagaya-ku, Tokyo
  25. Shinjuku-ku, Tokyo
  26. Suginami-ku, Tokyo
  27. Kofu-city, Yamanashi
  28. Tsuru-shi, Yamanashi
ALL GENDERS
2 Months+
years
MULTIPLE SITES
Pneumococcal DiseaseSafety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age
NCT04526574
  1. Birmingham, Alabama
  2. Phoenix, Arizona
  3. Tempe, Arizona
  4. Redding, California
  5. San Diego, California
  6. Jacksonville, Florida
  7. Orlando, Florida
  8. Orlando, Florida
  9. Savannah, Georgia
  10. Stockbridge, Georgia
  11. Metairie, Louisiana
  12. Norfolk, Nebraska
  13. Endwell, New York
  14. Rocky Mount, North Carolina
  15. Rocky Mount, North Carolina
  16. Cedar Park, Texas
  17. Norfolk, Virginia
  18. Mobile, Alabama
  19. Chandler, Arizona
  20. Phoenix, Arizona
  21. San Diego, California
  22. Walnut Creek, California
  23. Coral Gables, Florida
  24. Crystal River, Florida
  25. Hialeah, Florida
  26. Miami, Florida
  27. Miami, Florida
  28. Meridian, Idaho
  29. El Dorado, Kansas
  30. Wichita, Kansas
  31. Wichita, Kansas
  32. New Orleans, Louisiana
  33. Elkridge, Maryland
  34. Rockville, Maryland
  35. Saint Louis, Missouri
  36. Omaha, Nebraska
  37. Las Vegas, Nevada
  38. Las Vegas, Nevada
  39. Binghamton, New York
  40. Charlotte, North Carolina
  41. Greensboro, North Carolina
  42. Hickory, North Carolina
  43. Raleigh, North Carolina
  44. Raleigh, North Carolina
  45. Wilmington, North Carolina
  46. Fargo, North Dakota
  47. Cincinnati, Ohio
  48. Cincinnati, Ohio
  49. Cleveland, Ohio
  50. Franklin, Ohio
  51. Warwick, Rhode Island
  52. Little River, South Carolina
  53. Mount Pleasant, South Carolina
  54. Bristol, Tennessee
  55. Nashville, Tennessee
  56. Austin, Texas
  57. Fort Worth, Texas
  58. Fort Worth, Texas
  59. Houston, Texas
  60. McKinney, Texas
  61. Pearland, Texas
  62. San Antonio, Texas
  63. Tomball, Texas
  64. Tomball, Texas
  65. Draper, Utah
  66. Salt Lake City, Utah
  67. Salt Lake City, Utah
  68. South Jordan, Utah
  69. Richmond, Virginia
ALL GENDERS
65 Years+
years
MULTIPLE SITES
Pneumococcal Disease20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
NCT04382326
  1. Birmingham, Alabama
  2. Birmingham, Alabama
  3. Nampa, Idaho
  4. Baltimore, Maryland
  5. Baltimore, Maryland
  6. Brooklyn, New York
  7. Bayamon,
  8. Bayamon,
  9. San Juan,
  10. Cullman, Alabama
  11. Dothan, Alabama
  12. Phoenix, Arizona
  13. Fayetteville, Arkansas
  14. Bell Gardens, California
  15. Bellflower, California
  16. Covina, California
  17. Gardena, California
  18. Hawthorne, California
  19. Ontario, California
  20. Paramount, California
  21. Valencia, California
  22. West Covina, California
  23. Colorado Springs, Colorado
  24. Apopka, Florida
  25. Boynton Beach, Florida
  26. Gainesville, Florida
  27. Gainesville, Florida
  28. Hialeah, Florida
  29. Homestead, Florida
  30. Loxahatchee Groves, Florida
  31. Miami Lakes, Florida
  32. Miami, Florida
  33. Miami, Florida
  34. Tampa, Florida
  35. Chamblee, Georgia
  36. College Park, Georgia
  37. Columbus, Georgia
  38. Columbus, Georgia
  39. Ammon, Idaho
  40. Idaho Falls, Idaho
  41. Idaho Falls, Idaho
  42. Idaho Falls, Idaho
  43. Idaho Falls, Idaho
  44. Idaho Falls, Idaho
  45. Nampa, Idaho
  46. Ankeny, Iowa
  47. Des Moines, Iowa
  48. Des Moines, Iowa
  49. West Des Moines, Iowa
  50. El Dorado, Kansas
  51. Bardstown, Kentucky
  52. Louisville, Kentucky
  53. Baton Rouge, Louisiana
  54. Covington, Louisiana
  55. Haughton, Louisiana
  56. Metairie, Louisiana
  57. Baltimore, Maryland
  58. Frederick, Maryland
  59. Gulfport, Mississippi
  60. Missoula, Montana
  61. Lincoln, Nebraska
  62. Lincoln, Nebraska
  63. Albuquerque, New Mexico
  64. East Setauket, New York
  65. East Setauket, New York
  66. East Syracuse, New York
  67. Jackson Heights, New York
  68. Liverpool, New York
  69. Stony Brook, New York
  70. Stony Brook, New York
  71. Dayton, Ohio
  72. Dayton, Ohio
  73. Fairfield, Ohio
  74. South Euclid, Ohio
  75. East Norriton, Pennsylvania
  76. Erie, Pennsylvania
  77. Fort Washington, Pennsylvania
  78. Charleston, South Carolina
  79. Cheraw, South Carolina
  80. North Charleston, South Carolina
  81. Bristol, Tennessee
  82. Clarksville, Tennessee
  83. Kingsport, Tennessee
  84. Beaumont, Texas
  85. Beaumont, Texas
  86. Corpus Christi, Texas
  87. Houston, Texas
  88. Houston, Texas
  89. Longview, Texas
  90. McAllen, Texas
  91. McAllen, Texas
  92. San Antonio, Texas
  93. Kaysville, Utah
  94. Layton, Utah
  95. Murray, Utah
  96. Roy, Utah
  97. Saint George, Utah
  98. Syracuse, Utah
  99. Charlottesville, Virginia
  100. Charlottesville, Virginia
  101. Vancouver, Washington
  102. Guayama,
  103. Trujillo Alto,
ALL GENDERS
42 Days+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Postlicensure Observational Safety Study of 13vPnC Administered to Infants and Toddlers
Official Title Postlicensure Observational Safety Study of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) Administered in Routine Use to Infants and Toddlers
Brief Summary The purpose of the study is to expand the understanding of the safety profile of 13vPnC in routine use following licensure and introduction of the vaccine.
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Case-Only
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population 60,000 infants total: at least 43,000 infants who receive all 3 primary series doses of 13vPnC plus 15,000 additional infants who receive less than 3 doses of 13vPnC
Condition Pneumococcal Disease
Intervention Other: No Intervention
No Intervention
Study Groups/Cohorts 1
Intervention: Other: No Intervention
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: June 12, 2014)
53902
Original Estimated Enrollment
 (submitted: May 20, 2010)
60000
Actual Study Completion Date June 2013
Actual Primary Completion Date June 2013   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Infants starting vaccination with 13vPnC in the first 6 months of life who are members of the Northern California Kaiser Permanente healthcase system and who receive at least 1 dose of 13vPnC during the study observation period will be included. Infants must not have had 7vPnC at the time of 13vPnC dose administration.

Exclusion Criteria:

  • Infants and children who were previously vaccinated with any number of doses of 7vPnC will be excluded.
Sex/Gender
Sexes Eligible for Study:All
Ages 2 Months to 3 Years   (Child)
Accepts Healthy Volunteers Yes
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT01128426
Other Study ID Numbers 6096A1-4002
B1851044
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Pfizer
Study Sponsor Pfizer
Collaborators Kaiser Permanente
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date June 2014